NASDAQ:CHFS Nuwellis (CHFS) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free CHFS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.25▼$0.3050-Day Range$3.53▼$6.0252-Week Range$4.86▼$37.50Volume3.87 million shsAverage Volume467,323 shsMarket Capitalization$1.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Nuwellis alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Nuwellis Stock (NASDAQ:CHFS)Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.Read More Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. CHFS Stock News HeadlinesApril 10, 2024 | finance.yahoo.comNuwellis, Inc. (NUWE) Interactive Stock Chart - Yahoo FinanceSeptember 11, 2023 | investorplace.comWhy Is Nuwellis (NUWE) Stock Down Today?April 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.May 4, 2023 | forbes.comBetterHelp Online Therapy Review 2023March 11, 2023 | forbes.comBest Prenatal Vitamins Of 2023, According To ExpertsFebruary 20, 2023 | forbes.comBest Multivitamins For Kids In 2023, According To ExpertsOctober 19, 2022 | globenewswire.comNuwellis Announces Appointment of Chief Financial Officer - GlobeNewswireOctober 18, 2022 | streetinsider.comForm 424B4 Nuwellis, Inc. - StreetInsider.comApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.October 17, 2022 | uk.investing.comWhy Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday By Benzinga - Investing.com UKOctober 14, 2022 | uk.investing.comWhy Morgan Stanley Shares Are Trading Lower, Here Are 43 Stocks Moving In Friday's Mid-Day Session By Benzinga - Investing.com UKOctober 14, 2022 | benzinga.comWhy Morgan Stanley Shares Are Trading Lower, Here Are 43 Stocks Moving In Friday’s Mid-Day Session - Agri - BenzingaOctober 14, 2022 | uk.investing.comWhy IMARA Shares Are Trading Higher By Over 13%; Here Are 22 Stocks Moving Premarket By Benzinga - Investing.com UKOctober 14, 2022 | globenewswire.comNuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering - GlobeNewswireOctober 6, 2022 | marketscreener.comNuwellis : Results of Operations and Financial Condition - Form 8-K - Marketscreener.comOctober 6, 2022 | marketscreener.comNUWELLIS, INC. : Results of Operations and Financial Condition (form 8-K) - Marketscreener.comOctober 5, 2022 | marketscreener.comNUWELLIS, INC. : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) - Marketscreener.comOctober 4, 2022 | msn.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 2.66% - msnNOWOctober 4, 2022 | streetinsider.comNuwellis (NUWE) Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA - StreetInsider.comOctober 3, 2022 | benzinga.comNuwellis shares are trading higher after the company announced results of the AVOID-HF clinical study ana - BenzingaOctober 3, 2022 | in.investing.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 2.66% - Investing.com IndiaOctober 3, 2022 | finance.yahoo.comNuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting - Yahoo FinanceOctober 3, 2022 | globenewswire.comNuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting - GlobeNewswireSeptember 27, 2022 | benzinga.comNuwellis Announces Activation Of New Sites For Its Pivotal REVERSE-HF Trial - Nuwellis (NASDAQ:NUWE) - BenzingaSeptember 27, 2022 | finance.yahoo.comNuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial - Yahoo FinanceSeptember 27, 2022 | globenewswire.comNuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial - GlobeNewswireSeptember 23, 2022 | marketscreener.comNUWELLIS, INC. : Change in Directors or Principal Officers (form 8-K) - Marketscreener.comSee More Headlines Receive CHFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuwellis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/01/2021Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical Equipment Sub-IndustryN/A Current SymbolNASDAQ:CHFS Previous SymbolNASDAQ:SSH CUSIPN/A CIK1506492 Webwww.chf-solutions.com Phone(952) 345-4200FaxN/AEmployees66Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($279.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,110,000.00 Net Margins-254.26% Pretax MarginN/A Return on Equity-173.61% Return on Assets-131.01% Debt Debt-to-Equity RatioN/A Current Ratio6.87 Quick Ratio5.97 Sales & Book Value Annual Sales$5.51 million Price / Sales0.28 Cash FlowN/A Price / Cash FlowN/A Book Value$12.79 per share Price / Book0.02Miscellaneous Outstanding Shares6,037,000Free FloatN/AMarket Cap$1.52 million OptionableNot Optionable Beta1.55 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesNestor JaramilloPresident, Chief Executive Officer, CFO & DirectorVitaliy EpshteynSenior Vice President-Operations & EngineeringDavid LernerChief Technology OfficerThomas P. LynchSecretary, Chief Legal & Compliance OfficerLaurent DuhouxVice President-International Business DevelopmentKey CompetitorsTivic Health SystemsNASDAQ:TIVCNuwellisNASDAQ:NUWEENDRA Life SciencesNASDAQ:NDRAHelius Medical TechnologiesNASDAQ:HSDTPainReformNASDAQ:PRFXView All Competitors CHFS Stock Analysis - Frequently Asked Questions How were Nuwellis' earnings last quarter? Nuwellis, Inc. (NASDAQ:CHFS) announced its earnings results on Monday, March, 1st. The company reported ($1.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.91) by $0.34. The company earned $2.04 million during the quarter. Nuwellis had a negative net margin of 254.26% and a negative trailing twelve-month return on equity of 173.61%. When did Nuwellis' stock split? Nuwellis shares reverse split on the morning of Friday, October 13th 2017. The 1-20 reverse split was announced on Thursday, October 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 12th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Nuwellis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nuwellis investors own include Biocept (BIOC), Immutep (IMMP), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Zosano Pharma (ZSAN), Avinger (AVGR), Co-Diagnostics (CODX), iBio (IBIO), Inovio Pharmaceuticals (INO) and Onconova Therapeutics (ONTX). This page (NASDAQ:CHFS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuwellis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
